[go: up one dir, main page]

MX2017009044A - Metodo para el tratamiento de malignidades. - Google Patents

Metodo para el tratamiento de malignidades.

Info

Publication number
MX2017009044A
MX2017009044A MX2017009044A MX2017009044A MX2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A
Authority
MX
Mexico
Prior art keywords
malignities
treatment
supply
intratumoral
immunomodulators
Prior art date
Application number
MX2017009044A
Other languages
English (en)
Other versions
MX383277B (es
Inventor
H Pierce Robert
H Wright Jocelyn
Original Assignee
Oncosec Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Inc filed Critical Oncosec Medical Inc
Publication of MX2017009044A publication Critical patent/MX2017009044A/es
Publication of MX383277B publication Critical patent/MX383277B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención hace posible el suministro intratumoral de inmunomoduladores. En particular, proporciona el suministro de moléculas coestimuladoras al utilizar electroporación intratumoral.
MX2017009044A 2015-01-09 2016-01-08 Plasmido que codifica a un agonista coestimulador. MX383277B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101850P 2015-01-09 2015-01-09
US201562126300P 2015-02-27 2015-02-27
PCT/US2016/012759 WO2016112359A1 (en) 2015-01-09 2016-01-08 Method for the treatment of malignancies

Publications (2)

Publication Number Publication Date
MX2017009044A true MX2017009044A (es) 2018-01-11
MX383277B MX383277B (es) 2025-03-13

Family

ID=56356515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009044A MX383277B (es) 2015-01-09 2016-01-08 Plasmido que codifica a un agonista coestimulador.

Country Status (9)

Country Link
US (1) US20180000895A1 (es)
EP (2) EP3242947B1 (es)
JP (3) JP2018504403A (es)
CA (1) CA2973390A1 (es)
DK (1) DK3242947T3 (es)
ES (1) ES2809734T3 (es)
MX (1) MX383277B (es)
PL (1) PL3242947T3 (es)
WO (1) WO2016112359A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383277B (es) * 2015-01-09 2025-03-13 Oncosec Medical Inc Plasmido que codifica a un agonista coestimulador.
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
DK3474760T3 (da) 2016-06-27 2023-03-20 Galvanize Therapeutics Inc Generator og et kateter med en elektrode til at behandle en lungepassage
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
DK4218641T3 (da) 2017-12-26 2025-08-18 Galvanize Therapeutics Inc Optimering af energilevering til forskellige anvendelser
MX2020011618A (es) * 2018-05-02 2021-02-16 Oncosec Medical Inc Sistemas, métodos y aparatos de electroporación.
CN112739314A (zh) * 2018-08-08 2021-04-30 雪松-西奈医学中心 用于治疗癌症和自体免疫疾病的组合物和方法
CA3147592A1 (en) 2019-07-16 2021-01-21 Galary, Inc. Treatment of the reproductive tract with pulsed electric fields
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US20030049696A1 (en) 2001-06-07 2003-03-13 Norment Anne M. Regulatory T cells and uses thereof
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
WO2004110371A2 (en) * 2003-05-30 2004-12-23 University Of South Florida Method for the treatment of malignancies
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
AU2007239095B2 (en) * 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
US8586023B2 (en) * 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
MX354986B (es) * 2011-12-12 2018-03-28 Univ Pennsylvania Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
MX383277B (es) * 2015-01-09 2025-03-13 Oncosec Medical Inc Plasmido que codifica a un agonista coestimulador.

Also Published As

Publication number Publication date
JP7111384B2 (ja) 2022-08-02
PL3242947T3 (pl) 2021-01-11
CA2973390A1 (en) 2016-07-14
WO2016112359A1 (en) 2016-07-14
US20180000895A1 (en) 2018-01-04
EP3242947B1 (en) 2020-05-27
JP2021008481A (ja) 2021-01-28
JP2018504403A (ja) 2018-02-15
EP3799879B1 (en) 2025-06-04
EP3242947A4 (en) 2018-08-08
EP3242947A1 (en) 2017-11-15
JP2022137203A (ja) 2022-09-21
ES2809734T3 (es) 2021-03-05
DK3242947T3 (da) 2020-08-03
MX383277B (es) 2025-03-13
EP3799879A1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
MX2017009044A (es) Metodo para el tratamiento de malignidades.
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
ECSP17023281A (es) Inhibidores de mk2 y sus usos
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CR20170203A (es) Moleculas de unión a antígeno biespecíficas activadoras de células t
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
BR112016029076A8 (pt) Modulação de atividade de complemento
BR112016023707A2 (pt) método para produzir l-aminoácidos com o uso de uma bactéria alcalifílica
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX381278B (es) Composición para la estimulación ovárica controlada.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112017008097A2 (pt) método para tratar condições oculares
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения